Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives
-
By
-
Ellen Mayara Souza Cruz
-
Virginia Márcia Concato-Lopes
-
Mariana Barbosa Detoni
-
Manoela Daiele Gonçalves-Lens
-
Milena Cremer de Souza
-
Fabrício Seidy Ribeiro Inoue
-
Angélica Paulina Nunes
-
Elaine da Silva Siqueira
-
Ana Carolina Jacob Rodrigues
-
Yasmin Munhoz dos Santos-Destro
-
Natália Concimo Santos
-
João Manoel de Sousa Silva
-
Éder Ignácio da Silva
-
Maiara Voltarelli Providello
-
Danielle Lazarin-Bidóia
-
Fábio Rodrigues Ferreira Seiva
-
Wander Rogério Pavanelli
-
July 14, 2026
Clinical Scorecard: Chalcones as Multifaceted Modulators in Non-Small Cell Lung Cancer: Insights into Mechanisms and Treatment Implications
At a Glance
| Category | Detail |
|---|
| Condition | Non-Small Cell Lung Cancer (NSCLC) |
| Key Mechanisms | Chalcones modulate epithelial–mesenchymal transition, redox homeostasis, genotoxic stress, and regulated cell death pathways. |
| Target Population | Patients with Non-Small Cell Lung Cancer, particularly those with specific genetic alterations. |
| Care Setting | Oncology |
Key Highlights
- Lung cancer is the leading cause of cancer-related death worldwide.
- Chalcones exhibit strong anticancer effects by inducing apoptosis and inhibiting tumor progression.
- Structural modifications of chalcones can enhance selectivity and potency.
- Current treatments for NSCLC include chemotherapy, targeted therapies, and immunotherapy.
- Challenges include resistance to therapies and severe side effects.
Guideline-Based Recommendations
Diagnosis
- Lung tumors are classified as small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC).
Management
- Multimodal strategies including chemotherapy, targeted therapies, and immunotherapy are recommended based on disease stage.
Monitoring & Follow-up
- Monitor for resistance and adverse effects in patients undergoing treatment.
Risks
- Severe side effects from chemotherapy and potential resistance to targeted therapies.
Patient & Prescribing Data
Patients with NSCLC, particularly those with genetic alterations like EGFR mutations.
Chalcones may offer novel therapeutic options with potentially reduced toxicity.
Clinical Best Practices
- Consider structural modifications of chalcones to enhance therapeutic efficacy.
- Utilize a combination of treatment modalities tailored to individual patient profiles.
Related Resources & Content
